๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Guangzhou
Clinical trial register · China

Clinical Trials in Guangzhou, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage โ€” all 19052 matching records held by the registry are in this view. Synced 22 Sep 2026, 11:10 UTC
19052
Studies in scope
all four open statuses
11786
Recruiting now
open to new participants
2009
Lead sponsors
across recruiting studies
Top sites
Beijing 5484 Shanghai 3827 Guangzhou 3318 Hangzhou 1812 Wuhan 1343
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
Sun Yat-sen University451 Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University181 Nanfang Hospital, Southern Medical University138 AstraZeneca133 Guangdong Provincial People's Hospital81
Site location
Beijing5484 Shanghai3827 Guangzhou3318 Hangzhou1812 Wuhan1343
All 613 locations
Target enrolment
to

Trials with a site in Guangzhou

3318 of 19052 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Recruiting
A Study of Olverembatinib in SDH-deficient GIST.
NCT06640361GIST
Ascentage Pharma Group Inc.
Phase 3
40
Guangzhou
2024-11-11
Active, closed
Study of Lunsekimig (SAR443765) Compared With Placebo in Adults With High-risk Asthma
NCT06676319Asthma
Sanofi
Phase 2
556
Beijing, Changchun, Chengde, Chengdu, Foshan, Guangzhou, Guiyang, Hangzhou
2024-11-07
Recruiting
A Clinical Study to Evaluate the Efficacy and Safety of TQB3702 Tablets Combined With Immunochemotherapy for the Treatment of B-cell Lymphoma
NCT06566586B-cell Lymphoma
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 2
80
Beijing, Lanzhou, Guangzhou, Guigang, Nanning, Harbin, Anyang, Puyang
2024-11-06
Recruiting
Non-Helium Magnetoencephalography in Pediatric Brain Tumors
NCT06943742Pediatric Brain Tumor
Guangzhou Women and Children's Medical Center
Observational
100
Guangzhou
2024-11-05
Recruiting
Non-Helium Magnetoencephalography in Pediatric Refractory Epilepsy
NCT07064421Refractory Epilepsy in Children
Guangzhou Women and Children's Medical Center
Observational
100
Guangzhou
2024-11-05
Recruiting
Non-Helium Magnetoencephalography in Autism Spectrum Disorder
NCT07064967Autism Spectrum Disorder (ASD)
Guangzhou Women and Children's Medical Center
Observational
80
Guangzhou
2024-11-05
Active, closed
Study of HMPL-760 Plus R-GemOx Versus Placebo Plus R-GemOx in Relapsed/Refractory DLBCL
NCT06601504Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Hutchmed
Phase 2
61
Fuzhou, Guangzhou, Nanning, Wuhan, Harbin, Zhengzhou, Changsha, Nanchang
2024-11-05
Recruiting
A Trial of SHR-A2102 With Antitumor Therapy in Advanced Urothelial Carcinoma
NCT06639347Advanced Urothelial Carcinoma
Shanghai Hengrui Pharmaceutical Co., Ltd.
Phase 1/2
90
Guangzhou
2024-11-04
Recruiting
Comparison of Endoscopy and Esophagram for the Routine Evaluation of Anastomosis After McKeown Esophagectomy
NCT07043491Esophageal Cancer, Surgery-Complications
Sun Yat-sen University
Observational
2
Guangzhou
2024-11-04
Recruiting
Study of Patritumab Deruxtecan in Participants With Gastrointestinal Cancers (MK-1022-011) (HERTHENA-PanTumor02)
NCT06596694Gastrointestinal Cancer
Merck Sharp & Dohme LLC
Phase 1/2
180
Hefei, Fuzhou, Xiamen, Guangzhou, Nanning, Zhengzhou, Shanghai, Taiyuan
2024-11-03
Not yet open
A Multicenter, Single-arm, Open-label Study Evaluating the Safety and Efficacy of AK112 Combined With Chemotherapy as First-line Treatment for Non-squamous NSCLC Patients With BRAIN Metastases and Negative Driver Genes (IVO BRAIN)
NCT06684873NSCLC, Brain Metastasases
Sun Yat-sen University
Phase 2
55
Guangzhou
2024-11-02
Recruiting
Neoadjuvant Umbrella Trial for Patients With Unresectable Stage III NSCLC Harboring Rare Mutations.
NCT06563999Lung Cancer Stage III, Mutation
Sun Yat-sen University
Phase 2
120
Guangzhou
2024-11-01
Recruiting
Adjuvant PD-1 Blockade for High-risk Stage-II DMMR/MSI-H Colorectal Cancer
NCT06520683Colorectal Cancer, Microsatellite Instability High
Sun Yat-sen University
Phase 3
180
Guangzhou
2024-11-01
Recruiting
Umbilical Cord Blood NK Cell Therapy for High-Risk Pediatric Soft Tissue Sarcoma: Efficacy and Safety Study
NCT06848582Soft Tissue Sarcoma (STS)
Sun Yat-sen University
Not applicable
40
Guangzhou, Dongguan
2024-11-01
Recruiting
Phase I Study of Umbilical Cord Blood Natural Killer (NK) Cell Therapy for Children With High-risk, R/R Neuroblastoma.
NCT06631391Neuroblastoma
Sun Yat-sen University
Phase 1
30
Guangzhou
2024-11-01
Not yet open
Effect of a Myopia Prediction System on Myopia Prevention and Control
NCT06633393Myopia, Randomized Controlled Trials, Artificial Intelligence (AI)
Zhongshan Ophthalmic Center, Sun Yat-sen University
Not applicable
20,000
Guangzhou
2024-11-01
Active, closed
Safety and Efficacy of Blue Star MAX-5 Lenses in Myopia Control
NCT06647160Myopia, Progressive
Zhongshan Ophthalmic Center, Sun Yat-sen University
Not applicable
200
Guangzhou
2024-11-01
Recruiting
Photoacoustic Tomography in Assessment of Lower Extremity Artery Disease
NCT06579326Lower Extremity, Photoacoustic
Sun Yat-sen University
Observational
200
Guangzhou
2024-11-01
Recruiting
Orelabrutinib in Combination with R-CHOP for CD5-positive DLBCL Patients๏ผˆRocket Trial๏ผ‰
NCT06647940Diffuse Large B Cell Lymphoma (DLBCL)
Sun Yat-sen University
Phase 2
39
Guangzhou, Lanzhou, Dongguan, Shantou, Shenzhen, Zhaoqing, Zhuhai
2024-11-01
Not yet open
A Novel Serological Risk Model for Early Non-invasive Diagnosis of Cholangiocarcinoma
NCT06658587Cholangiocarcinoma
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Observational
60
Guangzhou
2024-11-01
Not yet open
Minimal Residual Disease Guiding Adjuvant Therapy in Stage I NSCLC
NCT06709274Non-Small Cell Lung Cancer
Guangdong Association of Clinical Trials
Not applicable
342
Dongguan, Foshan, Guangzhou, Shenzhen, Nanning, Guiyang, Wuhan, Changsha
2024-11
Not yet open
A Multicenter, Open Label Phase I Clinical Trial Evaluating the Safety and Pharmacokinetics of TQB2252 Injection in Subjects With Advanced Malignant Tumors
NCT06649656Advanced Cancers
Chia Tai Tianqing Pharmaceutical (Guangzhou) Co., Ltd.
Phase 1
100
Guangzhou
2024-11
Recruiting
A Study to Evaluate the Efficacy and Safety of Combination Therapy of BRII-179, BRII-835 and PEG-IFNฮฑ in Participants With Chronic Hepatitis B Virus (HBV) Infection (ENHANCE)
NCT06650852Chronic Hepatitis B Virus (HBV) Infection
Brii Biosciences Limited
Phase 2
250
Beijing, Guangzhou, Shenzhen, Shanghai, Chengdu, Hangzhou
2024-10-31
Active, closed
Zanubrutinib Plus Rituximab as Front-line Treatment for Mucosa-associated Lymphoid Tissue Lymphoma (MALT)
NCT06647732Mucosa-associated Lymphoid Tissue Lymphoma (MALT)
Sun Yat-sen University
Phase 2
42
Guangzhou
2024-10-30
By invitation
A Multicenter, Randomized, Controlled Trial of Prednisone Combined With Ursodeoxycholic Acid in the Treatment of Primary Biliary Cholangitis With Moderate to Severe Interface Hepatitis Characteristics
NCT06591468Primary Biliary Cholangitis (PBC)
Han Ying
Phase 2/3
244
Guangzhou, Xi'an
2024-10-30
Recruiting
Treating Loneliness In The Older Adult With Depression With tDCS
NCT06658795Major Depressive Disorder, Loneliness
Guangzhou Psychiatric Hospital
Not applicable
180
Guangzhou
2024-10-29
Recruiting
Home- vs Hospital-based Care of Anti-VEGF Treatment for Diabetic Macular Edema: Non-inferiority RCT
NCT06610747Diabetic Macular Edema
Zhongshan Ophthalmic Center, Sun Yat-sen University
Not applicable
308
Dongguan, Foshan, Guangzhou
2024-10-28
Recruiting
Comparing the Efficacy of Domestic Versus Imported Hearing Aids in ARHL
NCT06882889Age-related Hearing Loss, Hearing Loss, Sensorineural
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Not applicable
80
Guangzhou
2024-10-24
Active, closed
A Study of Remternetug (LY3372993) in Early Alzheimer's Disease (TRAILRUNNER-ALZ 3)
NCT06653153Alzheimer's Disease
Eli Lilly and Company
Phase 3
1,400
Beijing, Changchun, Changsha, Chengdu, Guangzhou, Hefei, Jinan, Luoyang
2024-10-24
Recruiting
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Antitumor Activity of ALK201 in Participants With Advanced Solid Tumors
NCT06656390Advanced Cancer, Advanced Solid Tumors
Shanghai Allink Biotherapeutics Co., Ltd.
Phase 1/2
202
Hefei, Fuzhou, Xiamen, Guangzhou, Shantou, Nanning, Chengde, Harbin
2024-10-24
Active, closed
Phase I Study of WJ47156 Monotherarpy and in Combination With Other Therapy in Advanced Solid Tumors
NCT06571422Advanced Malignant Solid Tumors
Shanghai Junshi Bioscience Co., Ltd.
Phase 1
59
Guangzhou
2024-10-23
Recruiting
Sintilimab Plus AVD in Pediatric Low/Moderate Risk Hodgkin Lymphoma: A Phase II Study
NCT06848569Classical Hodgkin Lymphoma
Sun Yat-sen University
Phase 2
73
Guangzhou
2024-10-23
Recruiting
Arsenous Acid for Refractory Triple-Negative Breast Cancer
NCT06678048Breast Cancer
Sun Yat-sen University
Phase 2
12
Guangzhou
2024-10-23
Recruiting
The Modified "Pills-in-the-Pocket" Strategy
NCT06657404Atrial Fibrillation (AF)
Yumei Xue
Not applicable
328
Guangzhou
2024-10-23
Recruiting
A Clinical Study of JMT101 in Combination With Osimertinib Versus Osimertinib Alone as First-Line Treatment for Patients With Locally Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC) Harboring Epidermal Growth Factor Receptor (EGFR) Sensitive Mutations
NCT06735391Locally Advanced or Metastatic Non-squamous NSCLC, Harboring EGFR Sensitive Mutations NSCLC, Previously Untreated Systematically NSCLC
Shanghai JMT-Bio Inc.
Phase 3
516
Guangzhou
2024-10-23
Recruiting
Application of Amide Proton Transfer-Weighted Imaging in Predicting Pathological Complete Response After Neoadjuvant Therapy of Rectal Cancer
NCT06719414Rectal Cancer
Sixth Affiliated Hospital, Sun Yat-sen University
Observational
320
Guangzhou, Maoming
2024-10-22
Recruiting
A Study to Learn How PF-06821497 (Mevrometostat) Works in Men With Metastatic Castration-resistant Prostate Cancer.
NCT06629779Metastatic Castration-Resistant Prostate Cancer
Pfizer
Phase 3
900
Wuhu, Beijing, Fuzhou, Guangzhou, Shantou, Guilin, Xinxiang, Zhengzhou
2024-10-22
Recruiting
Sintilimab With P-GEMOX Versus the P-GEMOX in the Teatment of Advanced-stage Extranodal Natural Killer/T Cell Lymphoma
NCT06583083Natural Killer/T-Cell Lymphoma, Nasal and Nasal-Type
Sun Yat-sen University
Phase 2
84
Guangzhou
2024-10-22
Recruiting
INTERSTELLAR - International Study Evaluating Lupus Outcomes After Anifrolumab Real World Use
NCT06314282Systemic Lupus Erythematosus (SLE)
AstraZeneca
Observational
200
Guangzhou, Hong Kong, Shenzhen, Zhongshan, Zhuhai
2024-10-22
Active, closed
TPC Combined With Cadonilimab VS. TPC Alone in Anti-PD-1 Resistant Recurrent or Metastatic Nasopharyngeal Carcinoma
NCT06664983Nasopharyngeal Cancinoma (NPC)
Sun Yat-sen University
Phase 3
84
Guangzhou
2024-10-21
Active, closed
A Study to Learn About the Investigational Medicine Called PF-06821497 (Mevrometostat) in Men With mCRPC Who Were Previously Treated With Abiraterone Acetate for Prostate Cancer (MEVPRO-1).
NCT06551324Metastatic Castrate Resistant Prostate Cancer (mCRPC)
Pfizer
Phase 3
600
Wuhu, Beijing, Chongqing, Fuzhou, Lanzhou, Guangzhou, Guilin, Wuhan
2024-10-21
Not yet open
Effects of Sleep Body Temperature on Body Composition
NCT06648109Blood Pressure Check (Hypertension Screening), Heart Rate, Aldosterone Disorder
Jinan University Guangzhou
Not applicable
40
Guangzhou
2024-10-20
Recruiting
A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer
NCT06662786Colorectal Neoplasms
Janssen Research & Development, LLC
Phase 3
1,000
Beijing, Changchun, Changsha, Guangzhou, Hangzhou, Harbin, Huizhou, Nanchang
2024-10-18
Recruiting
Study of BG-T187 Alone and in Combination With Other Therapeutic Agents in Participants With Advanced Solid Tumors
NCT06598800Advanced Solid Tumor
BeOne Medicines
Phase 1
153
Beijing, Chongqing, Fuzhou, Guangzhou, Nanning, Shijiazhuang, Harbin, Wuhan
2024-10-18
Active, closed
A Study of Dostarlimab in Participants With Untreated Locally Advanced Rectal Cancer in China
NCT06640049Neoplasms, Rectal
GlaxoSmithKline
Phase 2
23
Chengdu, Chongqing, Guangzhou, Hangzhou, Jinan, Kunming, Shanghai
2024-10-17
Recruiting
Long-term Impact of Inhaled Tobramycin for Pseudomonas Aeruginosa Eradication in Bronchiectasis (ERASE II)
NCT06760273Bronchiectasis Adult
Shanghai Pulmonary Hospital, Shanghai, China
Observational
364
Hefei, Beijing, Chongqing, Fuzhou, Guangzhou, Shenzhen, Zhanjiang, Nanning
2024-10-16
Recruiting
Safety and Effectiveness Evaluation of Spinal Laminectomy Robot
NCT06593574Lumbar Spinal Stenosis, Lumbar Disc Herniation
Peking University Third Hospital
Not applicable
70
Beijing, Guangzhou, Hangzhou
2024-10-15
Recruiting
Stereotactic Body Radiotherapy Followed by Tislelizumab Plus Platinum-based Chemotherapy Versus Tislelizumab Plus Platinum-based Chemotherapy as Neoadjuvant Therapy in Patients With Resectable Stage โ…ก-โ…ข Non-small Cell Lung Cancer: A Phase โ…ข, Randomized, Multicenter, Prospective Study
NCT06598527Lung Cancer (NSCLC)
Yang Hong
Phase 3
360
Guangzhou
2024-10-15
By invitation
Effect of Intrathecal Morphine on Quality of Recovery After Laparoscopic Colorectal Cancer Surgery
NCT06636864Laparoscopic Colorectal Cancer Surgery
Sun Yat-sen University
Not applicable
252
Guangzhou
2024-10-15
Active, closed
A Clinical Trial of TQB2102 for Injection in the Treatment of HER2 Low-Expressing Recurrent/Metastatic Breast Cancer
NCT06561607Breast Cancer
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 3
542
Bengbu, Hefei, Beijing, Quanzhou, Zhangzhou, Lanzhou, Wuwei, Guangzhou
2024-10-11
Recruiting
Aims to Explore the Safety, Tolerability, and Preliminary Efficacy of SCTB41 in Adult Patients with Advanced Malignant Solid Tumours.
NCT06600022Advanced Malignant Solid Tumours
Sinocelltech Ltd.
Phase 1/2
441
Guangzhou
2024-10-10
Recruiting
Efficacy Evaluation Study of BAT5906 and Lucentisยฎ in Patients With Diabetic Macular Edema
NCT07515079Diabetic Macular Edema (DME)
Bio-Thera Solutions
Phase 3
406
Beijing, Chongqing, Lanzhou, Guangzhou, Shantou, Shenzhen, Nanning, Zunyi
2024-10-09
Recruiting
TIPS Plus Half-dose Donafenib in AHCC with PVTT-associated Portal Hypertension
NCT06646198Hepatocellular Carcinoma with PVTT
Fei Gao
Phase 2
40
Guangzhou
2024-10-08
Active, closed
To Evaluate the Phase III Clinical Trial of TQH2722 Injection in the Treatment of Moderate to Severe Atopic Dermatitis
NCT06552520Atopic Dermatitis
Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.
Phase 3
500
Bengbu, Tongling, Wuhu, Beijing, Chongqing, Xiamen, Guangzhou, Shenzhen
2024-10-08
Recruiting
A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression โ‰ฅ 1%
NCT06561386Non-small Cell Lung Cancer
Bristol-Myers Squibb
Phase 3
1,000
Hefei, Beijing, Chongqing, Wanzhou, Fuzhou, Guangzhou, Huizhou, Liuzhou
2024-10-07
Recruiting
A Study of BG-C477 in Participants With Advanced Solid Tumors
NCT06596473Advanced Solid Tumors
BeOne Medicines
Phase 1
310
Beijing, Chongqing, Fuzhou, Guangzhou, Nanning, Harbin, Jiamusi, Zhengzhou
2024-10-03
Recruiting
Validation of High-Throughput Large-Format Tissue Preprocessing for Lung and Colorectal Cancer
NCT07239063CRC (Colorectal Cancer), Lung Cancer (Diagnosis)
Nanfang Hospital, Southern Medical University
Observational
1,000
Guangzhou
2024-10-01
Recruiting
Organoid-based Functional Precision Therapy for Advanced Breast Cancer
NCT06102824HER2-negative Breast Cancer, Advanced Breast Cancer
Guangdong Provincial People's Hospital
Phase 2
252
Guangzhou
2024-10-01
By invitation
Application of PDCA Cycle in Tracheal Intubation Training for Emergency Medicine Residents
NCT07146984Tracheal Intubation, Medical Education
Guangzhou Panyu Central Hospital
Observational
100
Guangzhou
2024-10-01
Recruiting
CD19/CD22 CAR-T Cell Therapy in MRD-Positive B-lineage Acute Lymphoblastic Leukemia in Children.
NCT06752785Acute Lymphoblastic Leukemia
Guangzhou Women and Children's Medical Center
Phase 1
10
Guangzhou
2024-10-01
Not yet open
The Correlation Characteristics Between Mental Health and Gut Microbiota of College Students in Qingyuan Vocational Education City
NCT06595095Depression, Anxiety
Zhujiang Hospital
Observational
600
Guangzhou
2024-10-01
Recruiting
Clinical Study of Super Transplantation in the Treatment of Severe ฮฒ-thalassemia
NCT06734520Thalassemia Majors (Beta-Thalassemia Major), Haplo-identical Donors
Guangzhou Women and Children's Medical Center
Not applicable
3
Guangzhou
2024-10-01
Recruiting
Efficacy and Safety of Finerenone in Patients With Primary Membranous Nephropathy
NCT06573411Primary Membranous Nephropathy
First Affiliated Hospital, Sun Yat-Sen University
Phase 4
116
Guangzhou
2024-09-30
Active, closed
Study to Assess Adverse Events and How Intravenously (IV) Infused Telisotuzumab Adizutecan (ABBV-400) Moves Through the Body of Adult Participants With Unresectable Locally Advanced/Metastatic Colorectal Cancer
NCT06464692Colorectal Cancer
AbbVie
Phase 1
31
Beijing, Guangzhou, Harbin, Zhengzhou, Wuhan, Nanchang, Shenyang, Hangzhou
2024-09-30
By invitation
Long-term Safety and Efficacy Evaluation of Lunsekimig (SAR443765) in Adult Participants With Asthma
NCT06609239Asthma
Sanofi
Phase 2
900
Beijing, Changchun, Changsha, Chengde, Guangzhou, Guiyang, Hefei, Hohhot
2024-09-30
Recruiting
A Study to Assess the Efficacy and Safety of HSK31858 in Participants With Non-Cystic Fibrosis Bronchiectasis
NCT06660992Non-cystic Fibrosis Bronchiectasis
Haisco Pharmaceutical Group Co., Ltd.
Phase 3
669
Guangzhou, Yixingcun
2024-09-30
Not yet open
Clinical Outcomes of Thoracodorsal Artery Flap in Oral and Maxillofacial Reconstruction
NCT06599801Oral Squamous Cell Carcinoma (OSCC)
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Observational
217
Guangzhou
2024-09-30
Recruiting
A Phase 2 Study of HB0017 in Psoriasis Patients
NCT06592274Psoriasis (PsO)
Huabo Biopharm Co., Ltd.
Phase 2
200
Bengbu, Guangzhou, Changsha, Wuxi, Zhenjiang, Changchun, Jinan, Jining
2024-09-30
Recruiting
Bactiseal Catheter Safety Registry Study
NCT06276543Hydrocephalus
Integra LifeSciences Corporation
Observational
200
Beijing, Guangzhou, Harbin, Wuhan, Shanghai, Chengdu
2024-09-29
Recruiting
Efficacy and Safety of Cytokine Adsorption and Plasma Exchange in Patients With ACLF and Sepsis
NCT06562803Acute-On-Chronic Liver Failure, Sepsis
Third Affiliated Hospital, Sun Yat-Sen University
Not applicable
192
Guangzhou
2024-09-27
Recruiting
Reduction of Postoperative Radiotherapy in Head and Neck Squamous Cell Carcinoma
NCT06630780Head and Neck Squamous Cell Carcinoma (HNSCC)
Sun Yat-sen University
Not applicable
50
Guangzhou
2024-09-26
Active, closed
A Study in Patients With Myasthenia Gravis in China
NCT06700616Myasthenia Gravis
AstraZeneca
Observational
1,199
Beijing, Chengdu, Fuzhou, Guangzhou, Guiyang, Harbin, Hebei, Henan
2024-09-26
Recruiting
A Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4)
NCT06585787Alzheimer Disease
Karuna Therapeutics, Inc., a Bristol Myers Squibb company
Phase 3
406
Beijing, Chongqing, Guangzhou, Shenzhen, Nanjing, Zhenjiang, Xi'an, Shanghai
2024-09-26
Recruiting
Pharmacokinetic Study of Oligonucleotides in Maixuekang Capsules
NCT06823895Healthy
Nanfang Hospital, Southern Medical University
Phase 1
12
Guangzhou
2024-09-25
Active, closed
A Phase 3, Placebo-Controlled Study to Investigate LP352 in Children and Adults With Dravet Syndrome (DS)
NCT06660394Dravet Syndrome
Longboard Pharmaceuticals
Phase 3
96
Beijing, Guangzhou, Shenzhen Shi, Wuhan, Shanghai Shi
2024-09-25
Recruiting
Study of YK012 in B-cell Acute Lymphoblastic Leukemia
NCT06580301B-cell Acute Lymphoblastic Leukemia
Excyte Biopharma Ltd
Phase 1/2
46
Guangzhou, Guiyang, Zhengzhou, Xuzhou, Nanchang, Changchun, Dalian, Shenyang
2024-09-25
Recruiting
A Study of Adebrelimab in Combination with Chemo with or Without Bevacizumab Neoadjuvant Therapy for Resectable NSCLC
NCT06775275Resectable Lung Non-Small Cell Carcinoma
The First Affiliated Hospital of Guangzhou Medical University
Phase 2
60
Guangzhou
2024-09-24
Recruiting
Comparative Study of Transaxillary Robotic Thyroidectomy With MRND Versus Conventional Open Surgery in N1b PTC
NCT06623578Papillary Thyroid Carcinoma, Lymphatic Metastasis
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Not applicable
876
Guangzhou
2024-09-23
Active, closed
Orthokeratology and 0.01% Atropine Sequential Treatment for Myopia Control
NCT06667037Myopia
Zhongshan Ophthalmic Center, Sun Yat-sen University
Not applicable
112
Guangzhou
2024-09-21
Recruiting
The Efficacy and Safety of Combining Probiotic VSL#3 With Vedolizumab for the Treatment of Moderate Ulcerative Colitis
NCT06609447Ulcerative Colitis
Second Affiliated Hospital, Zhejiang University, School of Medicine
Phase 4
100
Beijing, Chongqing, Guangzhou, Wuhan, Xiโ€™an, Chengdu, Hangzhou, Huzhou
2024-09-21
Recruiting
2 Courses of Concurrent Cisplatin Chemoradiotherapy After Surgery for High-risk Head and Neck Squamous Cell Carcinoma
NCT06492460Squamous Cell Carcinoma of Head and Neck
Sun Yat-sen University
Phase 3
422
Guangzhou, Guilin, Changsha, Nanjing
2024-09-20
Recruiting
Single-Incision Gasless Endoscopic Total Thyroidectomy Via Subclavian Approach Versus Open Surgery for PTC
NCT06592755Papillary Thyroid Carcinoma
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Observational
120
Guangzhou
2024-09-20
Not yet open
To Evaluate Recombinant Human Follicle Stimulating Hormone-CTP Fusion Protein Injection or Placebo Combined With Chorionic Gonadotropin for Injection
NCT06561594Idiopathic Hypogonadotropic Hypogonadism
Changchun GeneScience Pharmaceutical Co., Ltd.
Phase 3
60
Hefei, Beijing, Guangzhou, Shenzhen, Zhengzhou, Wuhan, Nanjing, Nanchang
2024-09-20
Not yet open
Preoperative (Chemo)Radiotherapy for Locally Recurrent Rectal Cancer
NCT06617052Locally Recurrent Rectal Cancer, Preoperative Chemoradiotherapy
Sixth Affiliated Hospital, Sun Yat-sen University
Observational
100
Guangzhou
2024-09-19
Recruiting
Systemic Therapy Alone or With Stereotactic Body Radiotherapy for Oligometastatic Kidney Cancer (STROKER Study)
NCT06726421Renal Cell Carcinoma (Kidney Cancer), Kidney Cancer Metastatic, Renal Cell Carcinoma Metastatic
Sun Yat-sen University
Phase 3
252
Fuzhou, Guangzhou, Wuhan, Changchun, Chengdu, Wenzhou, Beijing, Shanghai
2024-09-18
Active, closed
A Study to Assess Efficacy and Safety of Efgartigimod PH20 SC in Adults With Ocular Myasthenia Gravis
NCT06558279Myasthenia Gravis, Ocular
argenx
Phase 3
141
Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Jinan, Nanchang, Shanghai
2024-09-18
By invitation
Hematoporphyrin Photodynamic Therapy for Esophageal Cancer
NCT06437288Esophageal Cancer, Photodynamic Therapy
Sun Yat-sen University
Phase 4
198
Guangzhou
2024-09-18
Active, closed
A Study of Obexelimab in Patients With Systemic Lupus Erythematosus
NCT06559163Systemic Lupus Erythematosus
Zenas BioPharma (USA), LLC
Phase 2
190
Hefei, Beijing, Guangzhou, Shenzhen, Shijiazhuang, Nanchang, Pudong, Shanghai
2024-09-17
Active, closed
A Study to Assess the Efficacy and Safety of Afimkibart (Also Known as RO7790121) for Induction and Maintenance Therapy in Participants With Moderately to Severely Active Ulcerative Colitis
NCT06589986Moderately to Severely Active Ulcerative Colitis
Hoffmann-La Roche
Phase 3
400
Beijing, Binzhou, Changchun, Chengdu, Fuzhou, Guangzhou, Hefei, Huizhou
2024-09-17
Active, closed
Anvumetostat Alone or in Combination With Other Therapies in Subjects With Advanced Thoracic Tumors With Homozygous MTAP-deletion (Master Protocol) (MTAPESTRY 104).
NCT06333951Thoracic Tumors, Non-small Cell Lung Cancer
Amgen
Phase 1
49
Fuzhou, Guangzhou, Zhengzhou, Wuhan, Changchun, Chengdu, Beijing
2024-09-17
Recruiting
Evaluation of the Safety and Effectiveness of Pringle Method Combined With IVC Flow Limiting and Blocking Method in Laparoscopic Hepatectomy Based on Non-restrictive Fluid Therapy Strategy
NCT06594289Liver Tumor
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Not applicable
220
Guangzhou
2024-09-15
Recruiting
A Clinical Study on Recombinant Botulinum Toxin Type A (YY001) for Injection in The Treatment of Upper Limb Spasticity in Adults
NCT06783114Upper Limb Spasticity
Chongqing Claruvis Pharmaceutical Co., Ltd.
Phase 2/3
254
Hefei, Beijing, Chongqing, Guangzhou, Shenzhen, Kaifeng, Wuhan, Huai'an
2024-09-14
Recruiting
A Study of the Efficacy and Safety of Belimumab in Adults With Interstitial Lung Disease Associated With Connective Tissue Disease
NCT06572384Lung Diseases, Interstitial
GlaxoSmithKline
Phase 3
440
Beijing, Chengdu, Guangzhou, Hangzhou, Mianyang, Nanjing, Nanning, Shanghai
2024-09-11
Active, closed
A Study to Assess the Adverse Events and How Intravenously Infused Livmoniplimab in Combination With Budigalimab Moves Through the Bodies of Adult Chinese Participants With Locally Advanced or Metastatic Hepatocellular Carcinoma (HCC)
NCT06487559Hepatocellular Carcinoma (HCC)
AbbVie
Phase 1
3
Beijing, Fuzhou, Guangzhou, Harbin, Zhengzhou, Wuhan, Nanchang, Shenyang
2024-09-11
Recruiting
SBRT Followed by Chemoimmunotherapy of Toripalimab Plus Docetaxel and Cisplatin for Larynx Preservation in Patients with Locally Regionally Advanced Squamous Cell Carcinoma of the Larynx and Hypopharynx
NCT06611137Laryngeal Cancer, Hypopharynx Cancer
Sun Yat-sen University
Phase 2
35
Guangzhou
2024-09-11
Recruiting
Comparison Capsule Sparing Cystectomy and Radical Cystoprostatectomy in Men with Bladder Cancer
NCT05067101Bladder Cancer
Zhujiang Hospital
Not applicable
126
Guangzhou
2024-09-10
Recruiting
Efficacy and Safety of SR1375 in Adult Patients With CAP
NCT06577558Community-acquired Pneumonia
Shanghai SIMR Biotechnology Co., Ltd.
Phase 2
240
Fuyang, Beijing, Zhangzhou, Gaozhou, Guangzhou, Shantou, Yulin, Shijiazhuang
2024-09-10
Recruiting
Optimization of Keverprazan-amoxicillin Dual Therapy for Eradicating Helicobacter Pylori Infection
NCT06734260Helicobacter Pylori Eradication Rate
Eighth Affiliated Hospital, Sun Yat-sen University
Phase 3
477
Guangzhou, Puning, Shenzhen, Xiangyang
2024-09-10
Recruiting
Radiomics for Preoperative Jaw Cyst Differentiation
NCT06579768Jawbone Cysitc Lesion
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Observational
300
Guangzhou
2024-09-05
Active, closed
A Study of TAK-279 in Participants With Moderate-to-Severe Plaque Psoriasis
NCT06550076Plaque Psoriasis
Takeda
Phase 3
2,099
Beijing, Chongqing, Fuzhou, Guangzhou, Shijiazhuang, Wuhan, Zhenjiang, Shanghai
2024-09-04
Rows per page Showing 1601–1700 of 3318
Previous 15 16 17 18 19 Next
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 24 September 2026. https://priyalifescience.com/clinical-trials-china/city/guangzhou?page=17

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,052 studies in total at the last sync on 22 Sep 2026, 11:10 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 3,318 of those studies with a site in Guangzhou.

How many clinical trials are recruiting in Guangzhou?

1,972 of the 3,318 studies on this page are recruiting new participants as of the 22 Sep 2026, 11:10 UTC sync. A further 473 have not yet opened recruitment, 805 are active but closed to new participants, and 68 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.